Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some ...
Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results